Article

Multibody-Enabled Lysosome-Targeting Drug Conjugates for Target Protein Degradation and Combination Therapy

2026-02-18

Abstract excerpt

<title>Abstract</title> <p> Current lysosome-targeting chimeras (LYTACs) and antibody-drug conjugates (ADCs) face inherent limitations, including reliance on monospecific binders and target-dependent internalization efficiency. Here, we report a versatile therapeutic platform that overcomes these constraints by engineering a novel class of multivalent, multispecific binding proteins, termed <bold>Multibodies</b...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e4969b65-d556-5119-9594-54f44f144391
DOI: 10.21203/rs.3.rs-8651044/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Multibody-Enabled Lysosome-Targeting Drug Conjugates for Target Protein Degradation and Combination TherapyDOI 10.21203/rs.3.rs-8651044/v1Read

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?Semantic proximity Read

Dual PROTACs Versus Dual Inhibitors in Oncology: A Medicinal Chemistry and Linker Design PerspectiveSemantic proximity Read

PROTAC’ing oncoproteins: targeted protein degradation for cancer therapySemantic proximity Read

New-generation advanced PROTACs as potential therapeutic agents in cancer therapySemantic proximity Read

Welding PROxAb Shuttles: A modular approach for generating bispecific antibodies via site-specific protein-protein conjugationSemantic proximity Read

Covalently Engineered Nanobody Chimeras for Targeted Membrane Protein DegradationSemantic proximity Read

Targeting the Interplay of Proteins through PROTACs for the Management of Cancer and Associated DisordersSemantic proximity Read

Overcoming Cancer Drug Resistance Utilizing PROTAC TechnologySemantic proximity Read

Multispecific nanobody degraders co-deplete membrane receptors and enable targeted delivery of diverse payloadsSemantic proximity Read

Proteolysis‐targeting chimeras in drug development: A safety perspectiveSemantic proximity Read

Cancer Selective Target Degradation by Folate-Caged PROTACsSemantic proximity Read

Polymeric Lysosomal-Targeting Chimeras: Extracellular Targeted Protein Degradation Without Co-opting Lysosome-Targeting ReceptorsSemantic proximity Read